Search Results - "Bofill, F.J. Salvador"

P119 Recurrence Score® result by the 21-gene assay before and after systemic neoadjuvant chemotherapy in patients with HR+ HER2-breast cancer by Ciriaco, N., Vieites, B., Bellet, M., Castilla, C., Pardo, P. Gómez, Pérez-Luque, A., López, M.Á., Bofill, F.J. Salvador, Alfaro, L., García, J.M. Pérez, Espinosa-Bravo, M., Flannery, C., Hagen, C., Peg, V.

Get full text

339TiP SOLTI-1502 ARIANNA: Targeting PAM50 HER2-enriched intrinsic subtype with enzalutamide in hormone receptor-positive/HER2-negative metastatic breast cancer by Manso, L., Pernas, S., Margelí, M., Blanch, S., Adamo, B., Salvador Bofill, F.J., Moreno, D., González, X., Pascual, T., Ferrero-Cafiero, J.M., Perou, C.M., Prat, A., Oliveira, M.

Get full text

102P Long-term prediction of clinical outcomes by the 21-gene test in HR+ HER2- breast cancer patients with residual disease after neoadjuvant chemotherapy by Peg, V., de los Ángeles, N., Vieites, B., Bellet, M., Castilla, C., Gomez Pardo, P., Pérez-Luque, A., Lopez, M.A., Salvador Bofill, F.J., Alfaro, L., Perez Garcia, J.M., Espinosa-Bravo, M.

Get full text

73TiP SOLTI1710 PROMETEO II: Palbociclib in combination with letrozole in hormone receptor-positive (HR+)/HER2-negative residual disease after standard neoadjuvant chemotherapy (NAC) by Ciruelos, E., Salvador Bofill, F.J., Perello Martorell, A., Conejo, E. Alba, González-Farré, X., Palacios-Ozores, P., Merino, M., Villagrasa, P., Navarro, E. Vila, Pascual, T., Prat, A., Pernas Simon, S.

Get full text

202TiP SOLTI-1805 TOT-HER3 trial: A window-of-opportunity trial of patritumab deruxtecan (HER3-DXd) in patients with treatment-naïve, early breast cancer by Oliveira, M., Cejalvo Andujar, J.M., Margeli Vila, M., Tolosa Ortega, P., Martinez Saez, O., Salvador Bofill, F.J., Cruz Jurado, J., Luna Barrera, A.M., Arumi de Dios, M.A., Vidal Losada, M.J., Guerra, J.A., Pernas Simon, S., Villacampa Javierre, G., Gonzalez-farre, B., Sanfeliu Torres, E., Santhanagopal, A., Falato, C., Ferrero Cafiero, J.M., Pascual, T., Prat, A.

Get full text

Patritumab deruxtecan in untreated hormone receptor-positive/HER2-negative early breast cancer: final results from part A of the window-of-opportunity SOLTI TOT-HER3 pre-operative study by Oliveira, M., Falato, C., Cejalvo, J.M., Vila, M. Margelí, Tolosa, P., Salvador-Bofill, F.J., Cruz, J., Arumi, M., Luna, A.M., Guerra, J.A., Vidal, M., Martínez-Sáez, O., Paré, L., González-Farré, B., Sanfeliu, E., Ciruelos, E., Espinosa-Bravo, M., Pernas, S., Izarzugaza, Y., Esker, S., Fan, P.-D., Parul, P., Santhanagopal, A., Sellami, D., Villacampa, G., Ferrero-Cafiero, J.M., Pascual, T., Prat, A.

“…Patritumab deruxtecan (HER3-DXd) is a human epidermal growth factor receptor 3 (HER3)-directed antibody–drug conjugate composed of a fully human anti-HER3…”
Get full text

57TiP SOLTI-1910: Predicting olaparib sensitivity in patients with unresectable locally advanced/metastatic HER2-negative breast cancer with BRCA1/2, PALB2, RAD51C/D mutations or HRD by the RAD51 test: RADIOLA trial by Balmana, J., Pascual, T., Llop-Guevara, A., Tolosa, P., Blancas López-Barajas, I., Perez Lopez, M.E., Adamo, B., Teruel-Garcia, I., Ponce, J., González-Cordero, M., Viñas Villaro, G., Lema Roso, L., Salvador Bofill, F.J., M. Martinez, M.T., Guerrero, A.N.E., Prat, A., Serra Elizalde, V.

Get full text

LBA3 Patritumab deruxtecan (HER3-DXd) in early-stage HR+/HER2- breast cancer: Final results of the SOLTI TOT-HER3 window of opportunity trial by Prat, A., Falato, C., Pare Brunet, L., Martinez Saez, O., Cejalvo Andujar, J.M., Margeli Vila, M., Tolosa, P., Salvador Bofill, F.J., Cruz Jurado, J., Gonzalez-Farre, B., Sanfeliu Torres, E., Ciruelos, E.M., Espinosa-Bravo, M., Izarzugaza Peron, Y., Pernas Simon, S., Esker, S., Fan, P-D., Ferrero Cafiero, J.M., Pascual, T., Oliveira, M.

Get full text

332TiP SOLTI-1907 ATREZZO: Targeting hormonal receptor negative (HR-) or PAM50 non-luminal disease with atezolizumab in combination with trastuzumab and vinorelbine in HER2+ metastatic breast cancer (MBC) by Ciruelos, E.M., Pernas, S., Perelló, A., Lopez, A., Salvador Bofill, F.J., Cejalvo, J.M., Blancas, I., Ponce Lorenzo, J., Servitja, S., Perez, M., Cruz, J., Albacar, C., Escrivá-de-Romaní, S.I., Guerra, J.A., González-Santiago, S., Sanfeliu, E., Rodriguez, C., Tolosa, P., Ferrero-Cafiero, J.M., Prat, A.

Get full text

123MO BARBICAN: A randomized, phase II study to determine the contribution of ipatasertib to neoadjuvant chemotherapy plus atezolizumab in women with triple-negative breast cancer by Schmid, P., Bofill, F.J. Salvador, Bermejo, B., Phillips, M., Wheatley, D., Neus, F., Schem, C., Stradella, A., Mele, M., Salgado, A. Cortes, Quiroga, V., Torres, A. Antón, Cussac, A. Llombart, Zamora, E., Viale, G., Kuemmel, S., Prendergast, A., Mousa, K., Gluz, O., Cortés, J.

Get full text

103P PET-CT in localized breast cancer: Does it impact on the therapeutic decision? by Rodriguez, P. Macias, Perez, R. Buezas, Cejuela, M., Gonzalez, A. Falcon, Torralvo, A. Gil, Viñuales, M. Benavent, Alvarez, R.M., Cases, C., Borrego, M. Ruiz, Bofill, F.J. Salvador

Get full text

384TiP - Effectiveness of olaparib plus trastuzumab in HER2[+], BRCA–mutated (BRCAm) or homologous recombination deficient (HRD) advanced breast cancer (ABC) patients (pts). The OPHELIA study by Alés-Martínez, J.E., Morales, S., Fernández Abad, M., Sánchez-Rovira, P., Salvador Bofill, F.J., Lahuerta, A., García-Sáenz, J.A., Garau Llinas, I., Díaz Redondo, T., Ferrer, N., Carañana, V., López, R., Alonso Soler, S.E., Bermejo, B., de la Haba, J., Zamora, P., Balmana, J., López-Miranda, E., Cortés, J., Llombart Cussac, A.

“…In the OlympiAD trial the use of poly(adenosine diphosphate–ribose) polymerase inhibitor (PARPi) olaparib resulted in better progression–free survival (PFS)…”
Get full text

Effectiveness of olaparib plus trastuzumab in HER2[+], BRCA–mutated (BRCAm) or homologous recombination deficient (HRD) advanced breast cancer (ABC) patients (pts). The OPHELIA study by Alés-Martínez, J.E., Morales, S., Fernández Abad, M., Sánchez-Rovira, P., Salvador Bofill, F.J., Lahuerta, A., García-Sáenz, J.A., Garau Llinas, I., Díaz Redondo, T., Ferrer, N., Carañana, V., López, R., Alonso Soler, S.E., Bermejo, B., de la Haba, J., Zamora, P., Balmana, J., López-Miranda, E., Cortés, J., Llombart Cussac, A.

Get full text

130P Palbociclib in combination with letrozole in HR+/HER2- residual disease after standard neoadjuvant chemotherapy: Primary results of the SOLTI1710 PROMETEO II window of opportunity trial by Simon, S. Pernas, Torres, E. Sanfeliu, Villacampa, G., Bofill, F.J. Salvador, Martorell, A. Perello, Farre, X. González, Jiménez-Rodríguez, B., Salvador, M. Merino, Palacios-Ozores, P., Pascual, T., Alba, E., Villanueva, L., Galván, P., Prat, A., Ciruelos, E.M.

Get full text

LBA3 SOLTI-1507 IPATHER: Primary results of the phase Ib study of ipatasertib (IPAT) and dual anti-HER2 therapy with trastuzumab and pertuzumab (HP) in patients (pts) with PIK3CA mutant (mut) HER2+ advanced breast cancer (ABC) by Oliveira, M., Ciruelos, E.M., Morales Murillo, S., Salvador Bofill, F.J., Quiroga Garcia, V., Gavilá-Gregori, J., Cortegoso Mosquera, A.S., Vega Alonso, E., Henao, F., Servitja Tormo, S., Tolosa Ortega, P., Villacampa Javierre, G., Salvador, F., Paes Dias, M., Ferrero-Cafiero, J.M., González Farre, X., Pascual, T., Saura Manich, C.

Get full text

265TiP SOLTI-2201 ACROSS-TROP2 trial: A phase II study to identify predictive biomarkers of sacituzumab govitecan benefit and to understand resistance mechanisms in HR+/HER2- advanced or metastatic breast cancer by Ciruelos, E.M., Pascual, T., Vazquez, R. Villanueva, Cejalvo, J.M., Parraga, K. Amillano, Bofill, F.J. Salvador, López-Barajas, I. Blancas, Diez, A. Ferrando, Peron, Y. Izarzugaza, Puy, M. Borrell, Fernandez-Martinez, A., Javierre, G. Villacampa, Ferrero-Cafiero, J.M., Dias, M. Paes, Salvador, F., Oliveira, M.

Get full text

197P ATREZZO trial (SOLTI-1907): A phase II trial targeting estrogen receptor negative or PAM50 non-luminal disease with atezolizumab in combination with trastuzumab and vinorelbine in HER2-positive (HER2+) advanced breast cancer (ABC) - Interim analysis by Ciruelos, E.M., Ortega, P. Tolosa, Bofill, F.J. Salvador, González-Santiago, S., Miro, C.R. Albacar, Escrivá-De-Romaní, S., Gonzalez, A. Lopez, Simon, S. Pernas, Ponce, J., Martínez-Sáez, O., Cejalvo, J.M., Martorell, A. Perello, López-Barajas, I. Blancas, Guerra, J.A., Torres, E. Sanfeliu, Sanchez, C.A. Rodríguez, Villanueva, L., Villacampa, G., Prat, A., Pascual, T.

Get full text

124O Patritumab deruxtecan (HER3-DXd) in hormonal receptor-positive/HER2-negative (HR+/HER2-) and triple-negative breast cancer (TNBC): Results of part B of SOLTI TOT-HER3 window of opportunity trial by Oliveira, M., Pascual, T., Ortega, P. Tolosa, Vila, M. Margeli, Cejalvo, J.M., Jurado, J. Cruz, Bofill, F.J. Salvador, Arumi de Dios, M.A., Losada, M.J. Vidal, Simon, S. Pernas, Esker, S., Fan, P-D., Santhanagopal, A., Martínez-Sáez, O., Brasó-Maristany, F., Villacampa, G., Bayona, R. Sanchez, Ferrero-Cafiero, J.M., Falato, C., Prat, A.

Get full text

3MO HER2 expression and early response to patritumab deruxtecan (HER3-DXd) in early-stage hormone receptor-positive/HER2-negative (HR+/HER2-) breast cancer (BC): A correlative analysis from SOLTI-TOT-HER3 trial by Brasó-Maristany, F., Oliveira, M., Ortega, P. Tolosa, Vila, M. Margeli, Jurado, J. Cruz, Bofill, F.J. Salvador, Cejalvo, J.M., Arumi de Dios, M.A., Losada, M.J. Vidal, Simon, S. Pernas, Esker, S., Fan, P-D., Santhanagopal, A., Saez, O. Martinez, Villacampa, G., Bayona, R. Sanchez, Ferrero-Cafiero, J.M., Falato, C., Pascual, T., Prat, A.

Get full text

146P Updated survival analysis in NEOPERSUR trial: Neoadjuvant pertuzumab in a real-world population in the south of Spain by Gonzalez, A. Falcon, Jurado, J. Cruz, Valenti, E. Llabres, Cubero, R. Urbano, Alamo De La Gala, M.D.C., Martinez, A., Ambite, R.Á., Gonzalez, C.J. Rodriguez, Gongora, M. Amerigo, Perez, L. Rodriguez, Alvarez, M.P. Lopez, Sanchez-Rovira, P., Flores, E. Gonzalez, Carrasco, F. Henao, Calero, J.L. Bayo, Arbizu, M. Valero, Cutillas, A. Quilez, Bofill, F.J. Salvador, Borrego, M. Ruiz

Get full text